Cardiol Therapeutics Inc Class A (CRDL)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $127.69M
Last updated: Nov 17, 2026 at 4:22 PM ET
Cardiol Therapeutics Inc Class A (CRDL) Statistics
Cardiol Therapeutics Inc Class A (CRDL) has a market cap of $127.69M. Its share count is up 39.30% from a year earlier.
Total Valuation
| Market Cap | $127.69M |
|---|---|
| Latest price (Nov 17, 2026) | $0.97 |
Key Dates
| Last Earnings Date | Nov 12, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is down 4.73% over 52 weeks and trades 29.20% below its 50-day average.
| Beta (1Y) | 1.27 |
|---|---|
| 52-Week Change | -4.73% |
| 1-Month Change | -11.65% |
| 3-Month Change | -50.42% |
| 6-Month Change | -22.87% |
| 5-Year Change | -69.34% |
| Total Return (1Y) | -4.73% |
| Total Return (5Y CAGR) | -14.61% |
| Max Drawdown (1Y) | -59.45% |
| Max Drawdown (3Y) | -72.73% |
| Sharpe Ratio (1Y) | -0.09 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $1.37 |
| 200-Day Average | $1.30 |
| 52-Week Range | $0.88 to $2.34 |
| RSI (14 Days) | 32.4 |
| Average Volume (20 Days) | 542.60K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.26x current liabilities.
| Current Ratio | 6.26x |
|---|---|
| Quick Ratio | 6.26x |
Returns and Efficiency
Return on equity is -145.15% and return on assets is -121.84% over the last 12 months.
| Return on Equity (ROE) | -145.15% |
|---|---|
| Return on Assets (ROA) | -121.84% |
| Return on Capital Employed (ROCE) | -131.67% |
| ROA (5Y Average) | -78.89% |
| ROIC (5Y Average) | -80.69% |
Scores
CRDL has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was CAD 0 over the last 12 months.
| Revenue | CAD 0 |
|---|---|
| Operating Income | CAD -38.59M |
| Pretax Income | CAD -39.96M |
| Net Income | CAD -39.68M |
| EBITDA | CAD -36.47M |
| EBIT | CAD -36.55M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 83.94% of the CAD 33.00M in total assets.
| Working Capital | CAD 27.61M |
|---|---|
| Shareholder Equity | CAD 27.70M |
| Total Assets | CAD 33.00M |
| Total Liabilities | CAD 5.30M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After CAD 77.80K of capital spending, operating cash flow left CAD -21.68M of free cash flow.
| Operating Cash Flow | CAD -21.60M |
|---|---|
| Capital Expenditures | CAD 77.80K |
| Free Cash Flow | CAD -21.68M |
| Depreciation and Amortization | CAD 77.08K |
Trailing 12 months through Sep 30, 2026.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CRDL
What is CRDL's market cap?
Cardiol Therapeutics Inc Class A has a market cap of $127.69M.
How many shares of CRDL are outstanding?
Cardiol Therapeutics Inc Class A has 118.03M shares outstanding. The count is up 39.30% from a year earlier.
Does CRDL pay a dividend?
No. Cardiol Therapeutics Inc Class A does not pay a dividend.
CRDL pages: Overview, Charting, Financials, Statistics, Competitors